NCT06499298View on ClinicalTrials.gov

Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

CompletedOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

April 16, 2025

Study Completion Date

April 16, 2025

Conditions
Esophageal CancerGastroesophageal Junction Cancer
Interventions
DRUG

Nivolumab

As per product label, as prescribed by treating physician

Trial Locations (1)

200030

Local Institution - 0001, Shanghai

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06499298 - Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer | Biotech Hunter | Biotech Hunter